Group 1 - Halper Sadeh LLC is investigating iTeos Therapeutics, Inc. for potential violations related to its sale to Concentra Biosciences, LLC, which involves a cash offer of $10.047 per share and contingent value rights [1] - The contingent value rights include the right to receive 100% of iTeos' closing net cash exceeding $475 million and 80% of net proceeds from the sale of certain product candidates within six months post-closing [1] - WK Kellogg Co is being sold to The Ferrero Group for $23.00 per share in cash, prompting legal inquiries regarding shareholder rights [2] Group 2 - Halper Sadeh LLC may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4] - The firm represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Points - The proposed sale of iTeos Therapeutics, Inc. to Concentra Biosciences, LLC involves shareholders receiving $10.047 in cash per share, along with a non-transferable contingent value right [1] - The contingent value right includes the right to receive 100% of iTeos' closing net cash exceeding $475 million and 80% of net proceeds from the sale of certain product candidates within six months post-closing [1] - Kahn Swick & Foti, LLC is investigating whether the proposed transaction adequately values iTeos and the process leading to this valuation [1] Company and Industry Summary - iTeos Therapeutics, Inc. is currently in a proposed transaction to be acquired by Concentra Biosciences, LLC [1] - The investigation by Kahn Swick & Foti, LLC is focused on the adequacy of the transaction consideration and the valuation of the company [1][2] - The transaction is structured as a tender offer, indicating that timing is critical for stakeholders [3]

Group 1 - Class Action Attorney Juan Monteverde's firm has recovered millions for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report [1] - CARGO Therapeutics, Inc. is being investigated regarding its sale to Concentra Biosciences, LLC for $4.379 in cash per share, plus contingent value rights related to net cash and proceeds from specific therapies [1] - Hudson Global, Inc. is merging with Star Equity Holdings, Inc., with Hudson shareholders expected to own approximately 79% of the combined company post-transaction [1] - Breeze Holdings Acquisition Corp. is proposed to merge with YD Biopharma Limited, converting all ordinary shares into the right to receive shares of the surviving company [2] - Enzo Biochem, Inc. is selling to Battery Ventures for $0.70 per share in cash, with a shareholder vote scheduled for August 19, 2025 [3] Group 2 - Monteverde & Associates PC is a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court [4] - The firm emphasizes that no company, director, or officer is above the law, encouraging shareholders with concerns to reach out for additional information [5]

Core Viewpoint - Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sales of iTeos Therapeutics, Inc. and ZimVie Inc. [1][2] Group 1: iTeos Therapeutics, Inc. - iTeos Therapeutics, Inc. is set to be acquired by Concentra Biosciences, LLC for $10.047 in cash per share, along with a non-transferable contingent value right [1] - The contingent value right includes the right to receive 100% of iTeos' closing net cash exceeding $475 million and 80% of net proceeds from the disposition of certain product candidates within six months post-closing [1] Group 2: ZimVie Inc. - ZimVie Inc. is being sold to an affiliate of ARCHIMED for $19.00 in cash per share [2] Group 3: Legal Actions and Shareholder Rights - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief on behalf of shareholders [3] - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4]

Core Viewpoint - Rowley Law PLLC is investigating potential securities law violations related to the proposed acquisition of iTeos Therapeutics, Inc. by Concentra Biosciences, LLC, with stockholders set to receive $10.047 and one contingent value right for each share held [1]. Group 1 - The proposed acquisition transaction is expected to close in the third quarter of 2025 [1]. - Stockholders of iTeos Therapeutics will receive a total of $10.047 per share along with one contingent value right [1].

Core Viewpoint - The article discusses the investigation by Monteverde & Associates PC into the proposed acquisition of iTeos Therapeutics, Inc. by Concentra Biosciences, LLC, questioning the fairness of the deal. Group 1: Transaction Details - Concentra Biosciences, LLC plans to acquire iTeos Therapeutics, Inc. for $10.047 in cash per share [1] - The acquisition includes a non-transferable contingent value right, which entitles shareholders to 100% of iTeos' closing net cash exceeding $475 million and 80% of net proceeds from the sale of certain product candidates within six months post-closing [1] Group 2: Legal Context - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has a successful track record in recovering money for shareholders [1] - The firm operates from the Empire State Building in New York City and specializes in class action securities litigation [2]

Core Viewpoint - iTeos Therapeutics, Inc. has entered into a definitive merger agreement with Concentra Biosciences, LLC, where Concentra will acquire iTeos for $10.047 per share in cash, along with a contingent value right (CVR) [1][2][3] Group 1: Merger Agreement Details - The acquisition price includes $10.047 in cash per share of iTeos common stock and a CVR that entitles shareholders to 100% of iTeos' net cash exceeding $475 million and 80% of net proceeds from certain product candidates sold within six months post-closing [1][3] - The iTeos board of directors unanimously approved the merger, determining it to be in the best interests of all stockholders after a strategic review [2] - Concentra will initiate a tender offer by August 1, 2025, to acquire all outstanding shares of iTeos common stock, with the transaction expected to close in the third quarter of 2025, subject to customary closing conditions [3] Group 2: Conditions and Advisors - The closing of the offer is contingent upon the tender of shares representing at least a majority of outstanding shares and the availability of at least $475 million in cash at closing [3] - TD Cowen is serving as the exclusive financial advisor to iTeos, while Ropes & Gray LLP is providing legal counsel to iTeos, and Gibson, Dunn & Crutcher LLP is acting as legal counsel to Concentra [4]

Core Viewpoint - The article discusses the investigation by Monteverde & Associates PC into the acquisition of CARGO Therapeutics, Inc. by Concentra Biosciences, LLC, focusing on the fairness of the deal which includes a cash payment and contingent value rights for shareholders [1]. Group 1: Company Overview - CARGO Therapeutics, Inc. is being sold to Concentra Biosciences, LLC for $4.379 in cash per share, along with a non-transferable contingent value right [1]. - The contingent value right entitles shareholders to receive 100% of CARGO's closing net cash exceeding $217.5 million and 80% of net proceeds from the sale or licensing of specific CAR T therapies within two years post-closing [1]. Group 2: Legal Firm Background - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has a successful track record in recovering money for shareholders [1]. - The firm operates from the Empire State Building in New York City and specializes in class action securities litigation [2].

Group 1 - Halper Sadeh LLC is investigating CARGO Therapeutics, Inc. for potential violations of federal securities laws related to its sale to Concentra Biosciences, LLC, which is proposed at $4.379 in cash per share plus a contingent value right [1] - WNS (Holdings) Limited is also under investigation for its sale to Capgemini at $76.50 per share [2] - The firm may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options without any out-of-pocket payment for legal fees [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Viewpoint - CARGO Therapeutics has entered into a definitive merger agreement with Concentra Biosciences, where Concentra will acquire CARGO for $4.379 per share in cash, along with contingent value rights [1][2] Group 1: Merger Agreement Details - The acquisition price includes $4.379 in cash per share of CARGO common stock and one non-transferable contingent value right (CVR) [1] - The CVR entitles holders to receive 100% of CARGO's net cash exceeding $217.5 million and 80% of net proceeds from certain product candidates sold within two years post-closing [1] - The CARGO board unanimously approved the merger, deeming it in the best interests of all stockholders [2] Group 2: Tender Offer Process - Concentra will initiate a tender offer by July 21, 2025, to acquire all outstanding shares of CARGO common stock [3] - The closing of the offer is contingent upon the tender of a majority of outstanding shares and the availability of at least $217.5 million in cash at closing [3] - Approximately 17.4% of CARGO common stockholders have signed agreements to support the merger and tender their shares [3] Group 3: Advisors - TD Cowen is serving as the exclusive financial advisor to CARGO, while Latham & Watkins LLP is providing legal counsel to CARGO [4] - Gibson, Dunn & Crutcher LLP is acting as legal counsel to Concentra [4] Group 4: Company Background - CARGO Therapeutics is a biotechnology company focused on developing CAR T-cell therapies for cancer patients [5]